Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1609034 | 0.89 | KMT2A (0.46) | KMT2AGLAMAPTHPGDTSHR | |
| SCHEMBL1608249 | 0.85 | SMN1; SMN2 (0.55) | KMT2AGLAMAPTHPGDSMN1; SMN2 | |
| SCHEMBL1608941 | 0.82 | HPGD (0.58) | KMT2AGLAMAPTHPGDNPSR1 | |
| SCHEMBL1608247 | 0.79 | HPGD (0.55) | KMT2AGLAMAPTHPGDNPSR1 | |
| SCHEMBL1609127 | 0.76 | SMN1; SMN2 (0.52) | KMT2AGLAMAPTHPGDTSHR | |
| Trimetozine SCHEMBL114786 | 0.70 | MAPT (0.72) | KMT2AGLAMAPTHPGDPOLB | |
| SCHEMBL1608165 | 0.70 | HPGD (0.62) | KMT2AMAPTHPGDTSHRSMN1; SMN2 | |
| SCHEMBL1608957 | 0.70 | CES2 (0.55) | KMT2AGLAMAPTHPGDSMN1; SMN2 | |
| SCHEMBL1608153 | 0.69 | HPGD (0.47) | KMT2AMAPTHPGDTSHRSMN1; SMN2 | |
| SCHEMBL1608089 | 0.69 | KMT2A (0.46) | KMT2AGLAMAPTHPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8318785-B2 | Pharmaceutical compounds | ORION CORPORATION (FI) | 2012-11-27 | — | — | US | disclosed |
| US-20110086852-A2 | PHARMACEUTICAL COMPOUNDS | ORION CORPORATION (FI) | 2011-04-14 | — | — | US | disclosed |
| EP-1910325-B1 | NEW PHARMACEUTICAL COMPOUNDS | ORION CORP (FI) | 2010-10-06 | — | — | EP | disclosed |
| US-20090209532-A1 | PHARMACEUTICAL COMPOUNDS | ORION CORPORATION (FI) | 2009-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090209532-A1 | PHARMACEUTICAL COMPOUNDS | COMT, CYP2C19, UGT1A1 | KMT2A 2938/4885GLA 509/4885MAPT 1148/4885 |
| US-20110086852-A2 | PHARMACEUTICAL COMPOUNDS | COMT, CYP2C19, CYP3A4 | KMT2A 1989/4885GLA 420/4885MAPT 2131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.